Nektar Therapeutics (NASDAQ: NKTR) saw its stock price soar 5.22% in pre-market trading on Friday, following a 7.04% after-hours gain the previous day. The surge comes on the heels of the company's impressive third-quarter financial results and positive developments in its drug pipeline, which have rekindled investor confidence in the biopharmaceutical firm.

The company reported a quarterly loss of $1.87 per share, significantly outperforming the analyst consensus estimate of a $2.69 loss. This represents a 30.35% improvement over expectations and a substantial reduction in losses compared to the same period last year. Nektar's revenue also exceeded projections, reaching $11.79 million against an estimated $10.05 million, despite a year-over-year decrease.

Adding to the positive sentiment, Nektar recently received FDA Fast Track designation for rezpegaldesleukin in severe-to-very-severe alopecia areata, potentially accelerating its path to market. The company also bolstered its financial position by successfully closing a public stock offering in July, raising $115 million. With cash and investments totaling $270.2 million as of September 30, 2025, Nektar appears well-positioned to advance its promising drug candidates and maintain operations. These factors, combined with the strong Q3 performance, have contributed to the significant pre-market stock price increase and renewed investor optimism about the company's future prospects.